| The immunopeptidomic landscape of ovarian carcinomas H Schuster, JK Peper, HC Bösmüller, K Röhle, L Backert, T Bilich, B Ney, ... Proceedings of the National Academy of Sciences 114 (46), E9942-E9951, 2017 | 170 | 2017 |
| EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer KL Morel, AV Sheahan, DL Burkhart, SC Baca, N Boufaied, Y Liu, X Qiu, ... Nature cancer 2 (4), 444-456, 2021 | 138 | 2021 |
| Inhibition of CDK4/6 promotes CD8 T-cell memory formation M Heckler, LR Ali, E Clancy-Thompson, L Qiang, KS Ventre, P Lenehan, ... Cancer discovery 11 (10), 2564-2581, 2021 | 71 | 2021 |
| cIAP1/2 antagonism eliminates MHC class I–negative tumors through T cell–dependent reprogramming of mononuclear phagocytes K Roehle, L Qiang, KS Ventre, D Heid, LR Ali, P Lenehan, M Heckler, ... Science translational medicine 13 (594), eabf5058, 2021 | 32 | 2021 |
| HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy JK Peper, HC Bösmüller, H Schuster, B Gückel, H Hörzer, K Roehle, ... Oncoimmunology 5 (5), e1065369, 2016 | 24 | 2016 |
| Radiation combines with immune checkpoint blockade to enhance T cell priming in a murine model of poorly immunogenic pancreatic cancer CT Stump, K Roehle, N Manjarrez Orduno, SK Dougan Open biology 11 (11), 210245, 2021 | 16 | 2021 |
| Targeting EZH2 increases therapeutic efficacy of check-point blockade in models of prostate cancer AV Sheahan, KL Morel, DL Burkhart, SC Baca, DP Labbé, K Roehle, ... BioRxiv, 730135, 2019 | 7 | 2019 |
| Inhibition of CDK4/6 promotes CD8 T-cell memory formation. Cancer Discov 11: 2564–2581 M Heckler, LR Ali, E Clancy-Thompson, L Qiang, KS Ventre, P Lenehan, ... | 6 | 2021 |
| cIAP1/2 Antagonism Induces Antigen-Specific T Cell–Dependent Immunity KS Ventre, K Roehle, E Bello, AM Bhuiyan, T Biary, SJ Crowley, PT Bruck, ... The journal of immunology 210 (7), 991-1003, 2023 | 4 | 2023 |
| Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers H Schuster, J Peper, K Roehle, P Wagner, HG Rammensee US Patent 11,214,608, 2022 | 3 | 2022 |
| Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers H Schuster, J Peper, K Roehle, P Wagner, HG Rammensee US Patent 11,078,253, 2021 | 3 | 2021 |
| Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers H Schuster, J Peper, K Roehle, P Wagner, HG Rammensee US Patent 11,248,035, 2022 | 2 | 2022 |
| Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers H Schuster, J Peper, K Roehle, P Wagner, HG Rammensee US Patent 11,053,296, 2021 | 2 | 2021 |
| Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers J PEPER, HG Rammensee, K RÖHLE, H Schuster, P Wagner AU Patent App. 2,018,212,584 A, 2020 | 1 | 2020 |
| Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers H Schuster, J Peper, K Röhle, P Wagner, HG Rammensee US Patent 10,738,100, 2020 | 1 | 2020 |
| Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers H Schuster, J Peper, K Roehle, P Wagner, HG Rammensee US Patent App. 18/192,752, 2024 | | 2024 |
| Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers H Schuster, J Peper, K Roehle, P Wagner, HG Rammensee US Patent 11,919,940, 2024 | | 2024 |
| Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers H Schuster, J Peper, K Roehle, P Wagner, HG Rammensee US Patent App. 18/192,743, 2024 | | 2024 |
| Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers H Schuster, J Peper, K Roehle, P Wagner, HG Rammensee US Patent 11,858,978, 2024 | | 2024 |
| Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers H Schuster, J Peper, K Roehle, P Wagner, HG Rammensee US Patent 11,840,562, 2023 | | 2023 |
